At the news
? NEUTRALIMPACT 6/10 6-K filed Aug 19, 2026 at 09:16 ET
Chemomab reported Q2 2026 financial results and provided a corporate update centered on the proposed all-stock merger with Scipher Medicine. The company had $6.7M in cash as of June 30, 2026, with a net loss of $2.2M for the quarter. The merger, which values the combined company at $150M pre-money, would give Chemomab shareholders ~32% ownership and CVRs tied to nebokitug milestones, with the combined entity trading under 'SCIP'. The filing also includes a going-concern warning, noting cash runway only through Q1 2027 absent the merger closing, and the company has no approved products or revenue.
- Cash, cash equivalents and short-term bank deposits were $6.7M as of June 30, 2026, down from $8.0M as of March 31, 2026.
- Net loss for Q2 2026 was $2.2M, compared to $2.1M in Q2 2025.
- R&D expenses were $1.1M in Q2 2026 vs $1.3M in Q2 2025; G&A expenses were $1.1M vs $1.0M.
- Chemomab entered a definitive merger agreement with Scipher Medicine on July 7, 2026, an all-stock transaction valuing the combined company at $150M pre-money.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access